In human umbilical vein endothelial cells, Gallic Acid pretreatment decreased overall tube length per area compared with the untreated control group. In LPS-primed J774A.1 cells, Gallic Acid dose-dependently suppressed caspase 1 p20 release compared with the LPS plus ATP group. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Reduced Endothelial Tube Length
Cell-based study · human umbilical vein endothelial cell (HUVEC) [1]
Human umbilical vein endothelial cells were pretreated with Gallic Acid at 5, 10 or 15 μg/ml for 24 h. Tube length per area decreased to ~16.5%, 15.3% and 30.3% of the untreated control group, respectively.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10 or 15 μg/ml
- Exposure duration
- pretreated with 5, 10 or 15 μg/ml gallic acid for 24 h
- Vehicle
- dimethyl sulfoxide
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Gallic Acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Materials (S2); Materials and methods > Tube formation assay (S40); Results > Gallic acid inhibits angiogenesis (S76, S77); Figure 3 legend (S100, S101)
overall tube length per area: overall tube length per area; comparator: untreated control group — Materials and methods > Tube formation assay (S40); Results > Gallic acid inhibits angiogenesis (S77)
Dose-Dependent Suppression of Caspase Release
Cell-based study · J774A.1 cell [2]
LPS-primed J774A.1 cells were treated with Gallic Acid at 20, 40, 80 µM. Gallic Acid dose-dependently suppressed the release of caspase 1 p20 compared with the LPS plus ATP group.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20, 40, 80 µM
- Exposure duration
- primed with LPS (500 ng/ml) for 4 h, and gallic acid or the indicated compound was added for another 30 min
- Co-treatment
- Other interventions in this design: LPS 500 ng/ml; ATP 3 mM. Compound effect isolated by the comparison: compared with LPS plus ATP group.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Gallic Acid
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Cell Culture and Stimulation (S25); Results > Gallic Acid Inhibits Cell Death in Lipopolysaccharide-Primed and Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activator-Treated Macrophages (S110); Results > Gallic Acid Suppresses Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation and Pyroptosis (S124)
release of caspase 1 p20: release of caspase 1 p20; comparator: LPS plus ATP group — Results > Gallic Acid Suppresses Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation and Pyroptosis (S124)